FENC trades 58.7% below Wall Street's consensus target of $16.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FENC achieves its forward estimates and maintains a stable P/E multiple of 35.6x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 24, 2026, Fennec Pharmaceuticals Inc. (FENC) has a Wall Street consensus price target of $16.00, based on estimates from 8 covering analysts. With the stock currently trading at $10.08, this represents a potential upside of +58.7%. The company has a market capitalization of $350M.
Analyst price targets range from a low of $16.00 to a high of $16.00, representing a 0% spread in expectations. The median target of $16.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, FENC trades at a trailing P/E of -28.0x and forward P/E of 35.6x. Analysts expect EPS to grow +417.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LCTXLineage Cell Therapeutics, Inc. | $249M | $1.00 | — | — | Buy | — | 5 |
 SNOASonoma Pharmaceuticals, Inc. | $2M | $1.11 | — | — | — | — | — |
 HALOHalozyme Therapeutics, Inc. | $14.9B | $125.63 | $110.00 | -12.4% | Buy | 14.6x | 27 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.4B | $40.70 | $57.60 | +41.5% | Buy | 17.1x | 14 |
 PTCTPTC Therapeutics, Inc. | $5.0B | $60.59 | $102.89 | +69.8% | Buy | 51.6x | 26 |
 RCKTRocket Pharmaceuticals, Inc. | $250M | $2.29 | $5.32 | +132.3% | Buy | — | 19 |
 RAREUltragenyx Pharmaceutical Inc. | $1.5B | $15.65 | $25.46 | +62.7% | Buy | — | 34 |
 JAZZJazz Pharmaceuticals plc | $13.4B | $214.00 | $292.27 | +36.6% | Buy | 8.7x | 48 |
 PRGOPerrigo Company plc | $2.2B | $15.96 | $36.20 | +126.8% | Hold | 7.3x | 36 |
 PAHCPhibro Animal Health Corporation | $1.6B | $38.80 | $28.00 | -27.8% | Buy | 12.6x | 14 |
Quick answers to the most common questions about buying FENC stock.
The consensus Wall Street price target for FENC is $16, representing 58.7% upside from the current price of $10.08. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
FENC has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $16 implies 58.7% upside from current levels.
At a forward P/E of 35.5807x, FENC trades at a premium valuation. The consensus price target of $16 (58.7% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $16 for FENC, while the most conservative target is $16. The consensus of $16 represents the median expectation. These targets typically reflect 12-month expectations.
FENC is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FENC stock forecast based on 8 Wall Street analysts shows a consensus price target of $16, with estimates ranging from $16 (bear case) to $16 (bull case). The median consensus rating is "Buy".
FENC trades at a forward P/E ratio of 35.6x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on FENC, with a "Buy" consensus rating and $16 price target (58.7% upside). 8 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FENC analyst price targets range from $16 to $16, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.